We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+8.56%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$1.79B
(+14%)
Cap. Flow
+$849M
Cap. Flow
% of AUM
5.76%
Top 10 Holdings %
Top 10 Hldgs %
16.89%
Holding
1,178
New
178
Increased
473
Reduced
324
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$128M |
| 2 |
Intel
INTC
|
+$88.4M |
| 3 |
Prudential Financial
PRU
|
+$72.7M |
| 4 |
Lam Research
LRCX
|
+$62.6M |
| 5 |
SBA Communications
SBAC
|
+$58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$98.3M |
| 2 |
Target
TGT
|
+$86.8M |
| 3 |
Occidental Petroleum
OXY
|
+$74.7M |
| 4 |
Synchrony
SYF
|
+$61.6M |
| 5 |
Intercontinental Exchange
ICE
|
+$57.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.69% |
| 2 | Healthcare | 13.54% |
| 3 | Financials | 13.08% |
| 4 | Consumer Discretionary | 12.97% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SCS
251
DELISTED
Steelcase
SCS
| $12.5M | 0.08% |
828,278
+56,727
| +7% | +$818K |
|
252
MYR Group
MYRG
$5.66B
| $12.5M | 0.08% |
137,543
-20,643
| -13% | -$1.68M |
|
253
Enova International
ENVA
$6.06B
| $12.3M | 0.08% |
360,319
-73,177
| -17% | -$2.58M |
|
254
H&R Block
HRB
$5.39B
| $12.3M | 0.08% |
+524,746
| New | +$12.4M |
|
|
ICPT
255
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $12.3M | 0.08% |
613,888
+81,786
| +15% | +$1.62M |
|
256
DHT Holdings
DHT
$2.96B
| $12.2M | 0.08% |
1,879,387
+862,269
| +85% | +$5.29M |
|
257
EPAM Systems
EPAM
$4.86B
| $12M | 0.08% |
23,522
-889
| -4% | -$417K |
|
258
Agios Pharmaceuticals
AGIO
$2.25B
| $12M | 0.08% |
218,022
+14,746
| +7% | +$825K |
|
|
VRTV
259
DELISTED
VERITIV CORPORATION
VRTV
| $11.9M | 0.08% |
194,511
+11,025
| +6% | +$576K |
|
|
SNBR
260
DELISTED
Sleep Number
SNBR
| $11.9M | 0.08% |
+108,090
| New | +$12.3M |
|
261
Liberty Global Class A
LBTYA
$3.41B
| $11.8M | 0.08% |
436,274
+7,345
| +2% | +$198K |
|
262
Cabot Corp
CBT
$4.63B
| $11.8M | 0.08% |
207,707
-5,180
| -2% | -$304K |
|
263
Rush Enterprises Class A
RUSHA
$5.99B
| $11.8M | 0.08% |
409,208
+17,540
| +4% | +$561K |
|
264
Apogee Enterprises
APOG
$863M
| $11.7M | 0.08% |
287,525
-16,718
| -5% | -$630K |
|
265
Travere Therapeutics
TVTX
$5.37B
| $11.5M | 0.08% |
790,931
+149,759
| +23% | +$2.95M |
|
266
XPO
XPO
$24.2B
| $11.5M | 0.08% |
237,950
+110,393
| +87% | +$5.39M |
|
267
Benchmark Electronics
BHE
$2.78B
| $11.5M | 0.08% |
403,854
+50,188
| +14% | +$1.51M |
|
268
Enanta Pharmaceuticals
ENTA
$378M
| $11.4M | 0.08% |
259,553
+17,296
| +7% | +$847K |
|
|
VRNT
269
DELISTED
Verint Systems
VRNT
| $11.3M | 0.08% |
250,017
-75,756
| -23% | -$3.51M |
|
270
SFL Corp
SFL
$1.58B
| $11.2M | 0.08% |
1,470,427
+338,044
| +30% | +$2.77M |
|
271
Ovintiv
OVV
$17B
| $11.2M | 0.08% |
357,319
+187,800
| +111% | +$5.05M |
|
272
Pitney Bowes
PBI
$2.46B
| $11.2M | 0.08% |
1,274,492
-101,835
| -7% | -$849K |
|
273
Chemours
CC
$2.54B
| $11.1M | 0.08% |
319,186
+221,330
| +226% | +$7.33M |
|
274
Akebia Therapeutics
AKBA
$341M
| $11M | 0.07% |
2,907,334
+239,305
| +9% | +$806K |
|
|
PCH
275
DELISTED
PotlatchDeltic
PCH
| $10.9M | 0.07% |
205,672
+129,690
| +171% | +$7.47M |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2021 Portfolio in Review
As of Q2 2021, Jacobs Levy Equity Management held 1,178 positions worth $14.8B, up 14% from $13B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $849M of net new capital in Q2 2021, opening 178 new positions and adding to 473 existing holdings. Its largest new stake was Lam Research: 991,120 shares worth $64.5M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Qualcomm, an estimated $98.3M trimmed.
- Jacobs Levy Equity Management's largest Q2 2021 buy was Lam Research: 991,120 shares worth $64.5M.
- Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $128M increase.
- Jacobs Levy Equity Management's biggest Q2 2021 reduction was Qualcomm, cutting an estimated $98.3M.
- Jacobs Levy Equity Management fully exited Occidental Petroleum in Q2 2021, selling an estimated $74.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q2 2021.
- Jacobs Levy Equity Management opened 178 new positions and closed 161 in Q2 2021.
- Jacobs Levy Equity Management's portfolio value rose 14% quarter-over-quarter to $14.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.